
Marvel Biosciences' MB-204 shows positive preclinical results reversing Fragile X symptoms in mice.
Marvel Biosciences announced that its lead drug candidate, MB-204, demonstrated significant improvements in behavioral and cognitive functions in a Fragile X mouse model during preclinical trials. The drug showed dose-dependent efficacy and durable e...
